BMO Capital analyst Evan Seigerman raised the firm’s price target on Biogen (BIIB) to $196 from $165 and keeps a Market Perform rating on the shares following Q4 results. Revenue erosion from the multiple sclerosis business is expected to continue in 2026, but BMO Capital is growing more confident about the long-term opportunity for high-dose Spinraza and readouts for litifilimab in systemic lupus erythematosus, the firm told investors in a research note. BMO added that Q4 earnings outlines a path to growth in the future via Spinraza, even with “hiccups” in the quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Midday Fly By: Amazon sinks on spending plans, Stellantis takes big charge
- Morning Movers: Amazon, Molina Healthcare sink following quarterly results
- Biogen sees FY26 adjusted EPS $15.25-$16.25, consensus $14.95
- Biogen sees FY26 adjusted effective tax rate 17%-18%
- Biogen reports Q4 adjusted EPS $1.99, consensus $1.63